Current Hepatology Reports

, Volume 13, Issue 2, pp 159–170 | Cite as

Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

  • Paola Portillo
  • Sahzene Yavuz
  • Fernando Bril
  • Kenneth Cusi
Fatty Liver Disease (SA Harrison and J George, Section Editors)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is now a frequent cause of consultation for hepatologists and other health care providers. To a significant extent, this is because the metabolic abnormalities associated with obesity and type 2 diabetes mellitus (T2DM) promote liver disease and are more prevalent than ever before. Clinicians must be aware that insulin resistance and hyperglycemia are believed to worsen the natural history of NAFLD, fueling inflammation, hepatocyte injury (ballooning) and fibrosis. End-stage liver disease and hepatocellular carcinoma (HCC) develop more often in this setting. Interventions that reverse insulin resistance and hyperglycemia, may halt or ameliorate the disease process. Therefore, a comprehensive approach is needed for the successful management of these patients that addresses both, the liver-specific and the associated metabolic conditions. This review focuses on the mechanisms by which insulin resistance, and both lipo- and glucotoxicity, are believed to contribute to the development of NAFLD, and on the treatments tested in obese patients with T2DM and NAFLD, as a means to assist practitioners managing these complex patients.

Keywords

Fatty liver Nonalcoholic fatty liver disease (NAFLD) Steatosis Nonalcoholic steatohepatitis (NASH) Treatment Type 2 diabetes mellitus Obesity Insulin resistance Hyperglycemia Lipotoxicity Glucotoxicity Pioglitazone, Vitamin E Obeticholic acid Metformin Exenatide Liraglutide 

Notes

Acknowledgments

This work was supported by the American Diabetes Association (to K. C.) and a VA Merit Award (1 I01 CX000167-01; to K. C.).

Compliance with Ethics Guidelines

Conflict of Interest

Paola Portillo-Sanchez, Sahzene Yavuz, Fernando Bril and Kenneth Cusi declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.•
    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–90.PubMedGoogle Scholar
  2. 2.••
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. Recent guidelines elicited on the management of NAFLD are must-read for clinicians taking care of these patients. PubMedGoogle Scholar
  3. 3.••
    Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–25. e716. A comprehensive review on the mechanisms by which obesity predisoses to NAFLD, including how NAFLD relates to dyslipidemia, T2DM and cardiovascular disease. The review also elaborates on treatments, in particular on the role of pioglitazone, for this condition. PubMedGoogle Scholar
  4. 4.••
    Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837–58. A must-read state-of-the-art review on the epidemiology, pathogenesis and treatment to NAFLD. PubMedGoogle Scholar
  5. 5.
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.PubMedGoogle Scholar
  6. 6.••
    Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31. The best ultrasound-based screening study assessing the prevalence of NAFLD and NASH. PubMedGoogle Scholar
  7. 7.•
    Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837–45. The first study that carefully matched Hispanic and Caucasian patients for adiposity by dual X-ray absorptiometry in order to carefully examine the role of ethnicity without this confounding factor. PubMedGoogle Scholar
  8. 8.
    Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:1389–97.PubMedGoogle Scholar
  9. 9.
    Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35:873–8.PubMedCentralPubMedGoogle Scholar
  10. 10.••
    Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Relationship between disease severity, hyperinsulinemia and impaired insulin clearance in patients with nonalcoholic steatohepatitis (NASH). Hepatology. 2014. doi: 10.1002/hep.26988. Novel study that examines the etiology of hyperinsulinemia in NAFLD and the role of steatohepatitis and fibrosis in the developemnt of impaired insulin clearance at the level of the liver and peripheral tissues.
  11. 11.
    Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–9.PubMedGoogle Scholar
  12. 12.
    Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.PubMedGoogle Scholar
  13. 13.
    Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Phys India. 2009;57:205–10.Google Scholar
  14. 14.
    Kim S-KK, Choi YJ, Huh BW, Park SW, Lee EJ, Cho Y-W, et al. Non-alcoholic fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance. J Clin Endocrinol Metab. 2014. doi: 10.1210/jc.2013-4133.Google Scholar
  15. 15.
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–44.PubMedGoogle Scholar
  16. 16.
    Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:481–6.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complicat. 2013;27:293–300.PubMedGoogle Scholar
  18. 18.
    Bril F, Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus: Current controversies and future directions. Diabetes Care. 2014; (in press).Google Scholar
  19. 19.
    Bugianesi E, Gastaldelli A, Vanni E, Ganbino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.PubMedGoogle Scholar
  20. 20.
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320–30.PubMedGoogle Scholar
  21. 21.
    Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):1093–7.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Hardies J, Tio F, et al. Impact of glucose tolerance status on insulin sensitivity and disease severity in patients with NAFLD. Diabetes. 2012;61 suppl 1:A1761.Google Scholar
  23. 23.
    Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Amer J Gastroenterol. 2013;108:1861–8.Google Scholar
  24. 24.
    Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84–129.PubMedGoogle Scholar
  25. 25.
    Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol. 2006;40:68–76.PubMedGoogle Scholar
  26. 26.
    Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.PubMedGoogle Scholar
  27. 27.
    Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Hafeezunnisa: Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19:854–8.PubMedGoogle Scholar
  28. 28.
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 Suppl 1):S27–34.PubMedGoogle Scholar
  29. 29.
    Angulo P. GI Epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.PubMedGoogle Scholar
  30. 30.
    Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700–6.PubMedGoogle Scholar
  31. 31.
    Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.PubMedGoogle Scholar
  32. 32.
    Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–51.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913–24.PubMedCentralPubMedGoogle Scholar
  34. 34.••
    Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–6. Excellent prospective on the impact of risk factors such as obesity and T2DM in the progression of NASH. PubMedGoogle Scholar
  35. 35.
    Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017–23.PubMedGoogle Scholar
  36. 36.
    White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59. e1342.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–16.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713–23.PubMedGoogle Scholar
  40. 40.
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–89.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, et al. Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. Am J Physiol. 2001;280:E712–9.Google Scholar
  42. 42.
    Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 2010;52:727–36.PubMedCentralPubMedGoogle Scholar
  43. 43.••
    Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Mendez-Lucas A, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012;53:1080–92. Novel animal study on the role of mitochondrial dysfunction in the pathogenesis of hepatic steatosis. PubMedCentralPubMedGoogle Scholar
  44. 44.
    Wang SY, Kamat A, Pergola P, Swamy A, Tio F, Cusi K. Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism. 2011;60:1090–9.PubMedGoogle Scholar
  45. 45.
    Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58:1497–507.PubMedGoogle Scholar
  46. 46.
    Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, Krssak M, et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology. 2009;50:1079–86.PubMedGoogle Scholar
  47. 47.
    Schmid AI, Szendroedi J, Chmelik M, Krssak M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care. 2011;34:448–53.PubMedCentralPubMedGoogle Scholar
  48. 48.••
    Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14:804–10. Landmark study in humans offering strong evidence on the role of mitochondrial dysfunction, TCA cycle and gluconeogenesis in the pathogenesis of hepatic steatosis. PubMedCentralPubMedGoogle Scholar
  49. 49.
    Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, Schonfeld G, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology. 2010;139:149–53.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–88.PubMedGoogle Scholar
  51. 51.
    Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461–74.PubMedGoogle Scholar
  52. 52.
    Kashyap S, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol. 2004;287:E537–46.Google Scholar
  53. 53.
    Kantartzis K, Schick F, Haring HU, Stefan N. Environmental and genetic determinants of fatty liver in humans. Dig Dis. 2010;28:169–78.PubMedGoogle Scholar
  54. 54.•
    Naukkarinen J, Heinonen S, Hakkarainen A, Lundbom J, Vuolteenaho K, Saarinen L, et al. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia. 2014;57:167–76. Interesting study examining the genetic basis on NAFLD in monozygotic twins. PubMedGoogle Scholar
  55. 55.
    Bril F, Lomonaco R, Portillo-Sanchez P, Orsak B, Maximos M, Finch J, Webb A, Cusi K. Does Nonalcoholic Fatty Liver Disease (NAFLD) Develop in Insulin Sensitive Patients? Diabetes. 2014 (accepted abstract 1804-P).Google Scholar
  56. 56.
    Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49:2094–101.PubMedGoogle Scholar
  57. 57.
    Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Paris Prospective S: Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care. 2001;24:843–9.PubMedGoogle Scholar
  58. 58.
    Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–35.PubMedGoogle Scholar
  59. 59.
    Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829–38.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Jarvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008;135:122–30.PubMedGoogle Scholar
  61. 61.
    Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes. 2002;51:3014–9.PubMedGoogle Scholar
  62. 62.
    Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496–506.PubMedGoogle Scholar
  63. 63.
    Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab. 2013;2:133–41.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365–83.PubMedGoogle Scholar
  65. 65.
    Xu A, Wang Y, Keshaw H, Xu L, Lam K, Cooper G. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010;32:769–75.PubMedGoogle Scholar
  67. 67.
    Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29:351–66.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Shams ME, Al-Gayyar MM, Barakat EA. Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to lipid profile, oxidative stress and pro-Inflammatory cytokines. Sci Pharm. 2011;79:623–34.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–25.PubMedGoogle Scholar
  70. 70.
    Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60:832–8.Google Scholar
  71. 71.
    Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:1112–9.PubMedGoogle Scholar
  72. 72.
    Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750–7.PubMedGoogle Scholar
  73. 73.•
    Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clin Lipidol. 2012;7:471–81. Comprehensive review on the role of dyslipidemia and impact of lipid-lowering agents in NAFLD and NASH. Google Scholar
  74. 74.
    Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:2579–88.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Debosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose Transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J Biol Chem. 2014. doi: 10.1074/JBC.M113.527002.
  76. 76.
    Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993–9.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–71.PubMedCentralPubMedGoogle Scholar
  78. 78.
    Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, Ha V, Di Buono M, Jenkins AL, Leiter LA et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014. doi: 10.1038/ejcn.2014.8.
  79. 79.
    Gautier-Stein A, Soty M, Chilloux J, Zitoun C, Rajas F, Mithieux G. Glucotoxicity induces glucose-6-phosphatase catalytic unit expression by acting on the interaction of HIF-1alpha with CREB-binding protein. Diabetes. 2012;61:2451–60.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Meugnier E, Rome S, Vidal H. Regulation of gene expression by glucose. Curr Opin Clin Nutr Metab Care. 2007;10:518–22.PubMedGoogle Scholar
  81. 81.•
    Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1–14. Comprehensive review on the role of lifestyle changes and current and novel treatments for patients with NAFLD/NASH. PubMedGoogle Scholar
  82. 82.•
    Corrado R, Torres D, Harrison S. Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am. 2014;98:55–72. In-depth review on the role of treatment modalities in patients with NASH. PubMedGoogle Scholar
  83. 83.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.PubMedGoogle Scholar
  85. 85.
    Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005;90:3191–6.PubMedGoogle Scholar
  86. 86.
    Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156–63.PubMedCentralPubMedGoogle Scholar
  87. 87.••
    Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with NAFLD (The RAED2 randomized trial). Hepatology. 2013;58:1287–95. Well-designed controlled study comparing aerobic vs. resistance exercise for the treatment of NAFLD. PubMedGoogle Scholar
  88. 88.
    Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol. 2013;6:249–59.Google Scholar
  90. 90.
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639–44.PubMedGoogle Scholar
  91. 91.
    Harrison S, Brunt E, Fecht W, N-T BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology. 2009;49:80–6.PubMedGoogle Scholar
  92. 92.
    Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898–906.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–4.PubMedGoogle Scholar
  95. 95.
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–307.PubMedGoogle Scholar
  96. 96.
    Cusi K, Orsak B, Lomonaco R, Bril F, Ortiz-Lopez C, Hecht J, Webb A, Tio F, Darland CM, Hardies J. Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH. Hepatology. 2013; 58(Supplement 1):Abstract #82.Google Scholar
  97. 97.
    Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diabetes Rep. 2013;13:329–41.Google Scholar
  98. 98.••
    Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462–72. Large epidemiological study on the impact of thiazolidinedione treatment and risk of cancer. PubMedGoogle Scholar
  99. 99.
    Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol. 2014;51:91–101.PubMedGoogle Scholar
  100. 100.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.PubMedGoogle Scholar
  101. 101.
    Mells JE, Anania FA. The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis. 2013;33:343–57.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Sathyanarayana P, Jogi M, Muthupilla R, Ramkumar K, Samson S, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity. 2011;19:2310–5.PubMedGoogle Scholar
  103. 103.
    Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51:1584–92.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int Off J Int Study Liver. 2006;26:1015–7.Google Scholar
  105. 105.
    Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Amer J Gastroenterol. 2010;105:2707–9.Google Scholar
  106. 106.
    Mendoza CA, Mathew M, Chen J, Diaz N, Kaminski-Grant R, Darland C, et al. Exenatide promotes weight loss and improves insulin secretion, subclinical inflammation, and hepatic steatosis when replaced for premeal insulin in T2DM patients. Diabetes. 2009;58:A135.Google Scholar
  107. 107.
    Armstrong MJ, Houlihan DD, Rowe IA, Clausen WH, Elbrond B, Gough SC, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37:234–42.PubMedGoogle Scholar
  108. 108.
    Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. doi: 10.1136/bmjopen-2013-003995.
  109. 109.
    Abdul-Ghani MA, DeFronzo RA. Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013;14:1695–703.PubMedGoogle Scholar
  110. 110.
    Toderika Y, Ferguson N. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter. Cardiol Rev. 2014;22:97–104.PubMedGoogle Scholar
  111. 111.
    Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.PubMedCentralPubMedGoogle Scholar
  112. 112.
    List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, Ploton M, Mazuy C, Caron S, Tailleux A et al. The glucose sensing O-GlcNacylation pathway regulates the nuclear bile acid receptor FXR. Hepatology. 2013. doi: 10.1002/hep.26710.
  114. 114.•
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–82. e571. This study examines the effect of this novel agent on insulin sensitivity and other metabolic variables in patients with NAFLD. PubMedGoogle Scholar
  115. 115.
    Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Amer J Physiol. 2007;292:E829–35.Google Scholar
  116. 116.
    Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284–6.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Paola Portillo
    • 1
  • Sahzene Yavuz
    • 1
    • 2
  • Fernando Bril
    • 1
  • Kenneth Cusi
    • 1
    • 2
  1. 1.Division of Endocrinology, Diabetes and MetabolismUniversity of FloridaGainesvilleUSA
  2. 2.Malcom Randall VAMCGainesvilleUSA

Personalised recommendations